Search results for "Metabolic disease"

showing 10 items of 778 documents

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patien…

2015

OBJECTIVE: To compare lipid-lowering efficacy of adding alirocumab to rosuvastatin versus other treatment strategies (NCT01730053).METHODS: Patients receiving baseline rosuvastatin regimens (10 or 20 mg) were randomized to: add-on alirocumab 75 mg every-2-weeks (Q2W) (1-mL subcutaneous injection via pre-filled pen); add-on ezetimibe 10 mg/day; or double-dose rosuvastatin. Patients had cardiovascular disease (CVD) and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL (1.8 mmol/L) or CVD risk factors and LDL-C ≥100 mg/dL (2.6 mmol/L). In the alirocumab group, dose was blindly increased at Week 12 to 150 mg Q2W (also 1-mL volume) in patients not achieving their LDL-C target. Primary endpoi…

Monoclonal antibodymedicine.medical_specialtyTime FactorsSettore MED/09 - Medicina InternaInjections SubcutaneousHypercholesterolemiaUrology030204 cardiovascular system & hematologyPharmacologyAntibodies Monoclonal Humanizedlaw.inventionPCSK9Rosuvastatin03 medical and health sciences0302 clinical medicineDouble-Blind MethodEzetimibeRandomized controlled triallawmedicineClinical endpointHumansLow-density lipoprotein cholesterolRosuvastatinIn patient030212 general & internal medicineRosuvastatin CalciumAlirocumab; Ezetimibe; Low-density lipoprotein cholesterol; Monoclonal antibody; PCSK9; Rosuvastatin; Cardiology and Cardiovascular MedicineRetrospective StudiesAlirocumabDose-Response Relationship Drugbusiness.industryAnticholesteremic AgentsPCSK9Antibodies Monoclonalnutritional and metabolic diseasesCholesterol LDLEzetimibeRosuvastatin CalciumTreatment OutcomeCardiovascular DiseasesDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCardiology and Cardiovascular MedicineFollow-Up StudiesAlirocumabmedicine.drugAtherosclerosis
researchProduct

Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells

2013

International audience; Bleomycin (BLM) is an anticancer drug currently used for the treatment of testis cancer and Hodgkin lymphoma. This drug triggers cancer cell death via its capacity to generate radical oxygen species (ROS). However, the putative contribution of anticancer immune responses to the efficacy of BLM has not been evaluated. We make here the observation that BLM induces immunogenic cell death. In particular, BLM is able to induce ROS-mediated reticulum stress and autophagy, which result in the surface exposure of chaperones, including calreticulin and ERp57, and liberation of HMBG1 and ATP. BLM induces anti-tumor immunity which relies on calreticulin, CD8(+) T cells and inte…

MouseCancer TreatmentCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryHematologic Cancers and Related DisordersMice0302 clinical medicineTransforming Growth Factor beta[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyCytotoxic T cellImmune Response0303 health sciencesMultidisciplinaryCell DeathbiologyQRFOXP3Animal ModelsHematology3. Good healthCell biologyOncology030220 oncology & carcinogenesisMedicine[SDV.IMM]Life Sciences [q-bio]/ImmunologyImmunogenic cell deathFemaleLymphomasOncology AgentsResearch ArticleTumor Immunologycongenital hereditary and neonatal diseases and abnormalitiesProgrammed cell death[SDV.IMM] Life Sciences [q-bio]/ImmunologyScienceImmunologyAntineoplastic Agentschemical and pharmacologic phenomenaBleomycin03 medical and health sciencesModel OrganismsImmune systemCell Line TumorAnimalsHumansBiologyCell Proliferation030304 developmental biologyHodgkin Lymphomaurogenital systemCell growthImmunitynutritional and metabolic diseasesImmunologic SubspecialtiesChemotherapy and Drug TreatmentImmunity InnateCancer cellbiology.proteinClinical ImmunologyCalreticulinPLoS ONE
researchProduct

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.

2014

Item does not contain fulltext Plasma triglyceride concentration is a biomarker for circulating triglyceride-rich lipoproteins and their metabolic remnants. Common mild-to-moderate hypertriglyceridaemia is typically multigenic, and results from the cumulative burden of common and rare variants in more than 30 genes, as quantified by genetic risk scores. Rare autosomal recessive monogenic hypertriglyceridaemia can result from large-effect mutations in six different genes. Hypertriglyceridaemia is exacerbated by non-genetic factors. On the basis of recent genetic data, we redefine the disorder into two states: severe (triglyceride concentration >10 mmol/L), which is more likely to have a mono…

Multifactorial InheritanceSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Genome-wide association studyDisease030204 cardiovascular system & hematologyISCHEMIC-HEART-DISEASEBioinformaticshypertriglyceridaemia0302 clinical medicineEndocrinologyGENERAL-POPULATIONHypertriglyceridemiatreatmentmedicine.diagnostic_testREMNANT CHOLESTEROLCombined Modality Therapy3. Good healthLIPASE DEFICIENCYdiagnosiPLASMA TRIGLYCERIDESDENSITY-LIPOPROTEIN CHOLESTEROLCARDIOVASCULAR-DISEASEPractice Guidelines as TopicBiomarker (medicine)Multifactorial Inheritancemedicine.medical_specialty030209 endocrinology & metabolismHealth PromotionArticle03 medical and health sciencesPharmacotherapyInternal medicineInternal MedicinemedicineAnimalsHumansHOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAGenetic Predisposition to DiseaseAlleleGENOME-WIDE ASSOCIATIONLife Stylehypertriglyceridaemia; diagnosis; treatmentTriglyceridesGenetic testingbusiness.industryHypertriglyceridemianutritional and metabolic diseasesmedicine.diseaseEndocrinologyNONFASTING TRIGLYCERIDESbusinessBiomarkersThe lancet. Diabetesendocrinology
researchProduct

Long Daytime Napping Is Associated with Increased Adiposity and Type 2 Diabetes in an Elderly Population with Metabolic Syndrome

2019

Research examining associations between objectively measured napping time and type 2 diabetes (T2D) is lacking. This study aimed to evaluate daytime napping in relation to T2D and adiposity measures in elderly individuals from the Mediterranean region. A cross-sectional analysis of baseline data from 2190 elderly participants with overweight/obesity and metabolic syndrome, in the PREDIMED-Plus trial, was carried out. Accelerometer-derived napping was measured. Prevalence ratios (PR) and 95% confidence intervals (CI) for T2D were obtained using multivariable-adjusted Cox regression with constant time. Linear regression models were fitted to examine associations of napping with body mass inde…

Napfungimental disordersnutritional and metabolic diseasesWaist circumferenceType 2 diabetesPREDIMED-Plushuman activitiesActigraphypsychological phenomena and processesBody mass index
researchProduct

Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project

2021

Abstract Background Hyperuricemia is commonly observed in patients with chronic kidney disease (CKD). However, a better understanding of the relationship among uric acid (UA) values, glomerular filtration rate (GFR) and albuminuria may shed light on the mechanisms underlying the excess of cardiovascular mortality associated with both chronic kidney disease and hyperuricemia and lead to better risk stratification. Our main goal was to study the relationships between serum uric acid and kidney disease measures (namely estimated GFR [eGFR] and albuminuria) in a large cohort of individuals at cardiovascular risk from the URic acid Right for heArt Health (URRAH) Project database. Methods Clinica…

NephrologyAdultMalemedicine.medical_specialtySettore MED/09 - Medicina Interna030232 urology & nephrologyAllopurinolRenal functionHyperuricemia030204 cardiovascular system & hematologyKidneyurologic and male genital diseasesGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSerum uric acidRisk FactorsInternal medicineDiabetes mellitusmedicineeGFRHumansAlbuminuriaHyperuricemiaRenal Insufficiency ChronicAgedbusiness.industryAlbuminuria; Cardiovascular risk; Serum uric acid; eGFRnutritional and metabolic diseaseseGFR.Middle Agedmedicine.diseaseCardiovascular riskUric AcidchemistryNephrologyAlbuminuriaUric acidAlbuminuria; Cardiovascular risk; eGFR; Serum uric acidOriginal ArticleFemalemedicine.symptombusinessmedicine.drugKidney diseaseGlomerular Filtration Rate
researchProduct

Non-Celiac Wheat Sensitivity Diagnosed by Double-Blind Placebo-Controlled Challenge: Exploring a New Clinical Entity.

2012

Non-Celiac Wheat Sensitivity Diagnosed by Double-Blind Placebo-Controlled Challenge: Exploring a New Clinical Entity

Non-Celiac Wheat SensitivityPediatricsmedicine.medical_specialtySettore MED/09 - Medicina InternaHepatologybusiness.industryNon-celiac gluten sensitivityGastroenterologyDouble-Blind Placebo-Controlled Challengenutritional and metabolic diseasesfood and beveragesmedicine.diseasePlaceboFood hypersensitivitydigestive system diseasesDouble blindNon-Celiac Wheat Sensitivity; Double-Blind Placebo-Controlled Challenge;Severity of illnessmedicineDifferential diagnosisbusinessNon-celiac gluten sensitivityIrritable bowel syndromeWheat allergy
researchProduct

Need for liver evaluation in polycystic ovary syndrome

2007

Medicine is changing and requires a more in-depth knowledge also in fields that were previously considered completely different and dedicated to other specialists. A good example of this general trend is the paper by Cerda et al. [1] that shows a high prevalence of nonalcoholic fatty liver disease (NAFLD) in women with Polycystic Ovary Syndrome (PCOS). The authors studied 41 young women with PCOS and found that 17 patients (41%) had NAFLD. In addition, 7 patients with NAFLD had increased aminotransferase levels raising the possibility of a transition to nonalcoholic steatohepatitis (NASH). Other reports have shown similar data recently [2–5]. It is time therefore that doctors caring for pat…

Nonalcoholic steatohepatitisMetabolic Syndromemedicine.medical_specialtySettore MED/12 - GastroenterologiaSettore MED/09 - Medicina InternaHepatologyPCOS Liver function NASH NAFLDbusiness.industrynutritional and metabolic diseasesmedicine.diseaseGastroenterologyPolycystic ovarySettore MED/13 - EndocrinologiaFatty LiverLiver Function TestsInternal medicineNonalcoholic fatty liver diseasePrevalenceMedicineHumansFemalebusinessPolycystic Ovary Syndrome
researchProduct

Recent Advances in Biotechnological Methods for Wheat Gluten Immunotoxicity Abolishment – a Review

2021

Due to the increasing incidence of gluten intolerance, researchers are focusing on finding ways to eliminate immunotoxicity of wheat, this would allow the use of wheat products for gluten-intolerant consumers. The article reviews recent studies on biotechnological methods to eliminate and reduce the immunogenicity of wheat products. So far, many gluten removal methods have been proposed, but their efficacy levels were quite different. Enzymatic treatment of gluten fragments can be considered the simplest and non-invasive tool to eliminate the toxicity of gliadins and glutenins. For this purpose, various endogenous enzymes derived from cereals, and also those of bacterial, fungal, plant, and…

Nutrition and DieteticsChemistrybusiness.industrynutritional and metabolic diseasesfood and beveragesdetoxified wheatWheat glutenlcsh:TX341-641wheat immunogenicityBiotechnologybusinesslcsh:Nutrition. Foods and food supplyceliac diseasegluten hydrolysisFood SciencePolish Journal of Food and Nutrition Sciences
researchProduct

Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardi…

2014

Data on the long-term metabolic side-effects associated with antipsychotics are scarce. Prospective longitudinal studies in medication-naive patients with a first episode of psychosis are a valuable source of information as they provide an assessment prior to the antipsychotic exposure and minimize the effect of potential confounding factors. The aim of this study was to assess the course of weight gain and the incidence of metabolic abnormalities during the first 3 yr of antipsychotic treatment. Data were collected from a cohort of 170 first-episode psychosis patients. They were randomly assigned to haloperidol (32%); olanzapine (32%) and risperidone (36%). The dose used was flexible. The …

OlanzapineAdultMaleMedication-naivemedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentWeight GainBenzodiazepinesYoung AdultMetabolic DiseasesRisk FactorsMetabolic side effectsInternal medicinemedicineHumansAntipsychoticsPharmacology (medical)Prospective StudiesAntipsychoticPsychiatryProspective cohort studyPharmacologyFirst episodeRisperidoneMiddle AgedRisperidoneFirst-episode psychosisCardiovascular riskCritical periodPsychiatry and Mental healthTolerabilityPsychotic DisordersOlanzapineCohortHaloperidolmedicine.symptomPsychologyWeight gainmedicine.drugAntipsychotic Agents
researchProduct

Correction:Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrom…

2020

Lynch syndrome (LS) results from pathogenic variants in the mismatch repair (MMR) genes and is the most common hereditary cancer syndrome, affecting an estimated 1 in 300 individuals. Pathogenic variants in each of the MMR genes path_MLH1, path_MSH2, path_MSH6, and path_PMS2 result in different risks for cancers in organs including the colorectum, endometrium, ovaries, stomach, small bowel, bile duct, pancreas, and upper urinary tract. Accurate estimates of these risks are essential for planning appropriate approaches to the prevention or early diagnosis of cancers but the robustness of previous studies has been limited by factors including retrospective design,1,2 lack of validation in ind…

OncologyMaleColorectal cancer*Lynch syndromePenetranceDNA Mismatch Repair0302 clinical medicineDatabases GeneticMalalties hereditàriesProspective StudiesCàncer*PMS2Genetics (clinical)Mismatch Repair Endonuclease PMS2Cancer0303 health sciencesSex CharacteristicsFactors de risc en les malalties1184 Genetics developmental biology physiologyMLH1Middle Aged16. Peace & justiceLynch syndrome3. Good healthDNA-Binding ProteinsMutS Homolog 2 Proteinsyöpägeenit*MSH2030220 oncology & carcinogenesis*MSH6030211 gastroenterology & hepatologyDNA mismatch repairFemalegeneettiset tekijätMutL Protein Homolog 1Genetic diseasesAdultmedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesRisk factors in diseasessuolistosyövätMUTATION CARRIERSMLH1Risk AssessmentArticlesukupuoliAge and gender03 medical and health sciencesInternal medicinemedicineHumansGenetic Predisposition to DiseaseLynchin oireyhtymäGene030304 developmental biologyAgedbusiness.industryEndometrial cancerCorrectionnutritional and metabolic diseasesCancer*MLH1MSH6medicine.diseaseColorectal Neoplasms Hereditary NonpolyposisSurvival Analysisdigestive system diseasesMSH2MSH6Lynch syndromePMS2MSH2Mutation3111 BiomedicineikäbusinessOvarian cancer
researchProduct